Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF

Prior studies have demonstrated an association of depression with adverse clinical outcomes in patients with HFrEF, but the possible mechanisms responsible for the association are not unserstood. 142 men and women with HFrEF were enrolled through HF clinics and followed over time. At baseline and 6-...

Full description

Saved in:
Bibliographic Details
Published inmedRxiv : the preprint server for health sciences
Main Authors Sherwood, Andrew, Blumenthal, James A, Mentz, Robert J, Koch, Gary G, Rogers, Joseph G, Chang, Patricia P, Chien, Christopher, Adams, Jr, Kirkwood F, Rose-Jones, Lisa J, Jensen, Brian C, Johnson, Kristy S, Hinderliter, Alan L
Format Journal Article
LanguageEnglish
Published United States 27.09.2023
Subjects
B-Type natriuretic peptide
Heart failure
ejection fraction
depression
HFrEF
Online AccessGet more information

Cover

More Information
Summary:Prior studies have demonstrated an association of depression with adverse clinical outcomes in patients with HFrEF, but the possible mechanisms responsible for the association are not unserstood. 142 men and women with HFrEF were enrolled through HF clinics and followed over time. At baseline and 6-months, depression was assessed by the Beck Depression Inventory (BDI-II) and disease activity by B-type natriuretic peptide (BNP). Proportional Hazards Regression Models assessed the contribution of depressive symptoms and HFrEF disease biomarkers on death or cardiovascular hospitalization. Over a median follow-up period of 4 years, 42 patients (30%) died, and 84 (60%) had cardiovascular hospitalizations. A 10-point higher baseline BDI-II score was associated with a 35% higher hazard of death or cardiovascular hospitalization. Greater baseline BDI-II scores were associated with poorer HF self-care maintenance (R=-0.30, p<0.001) and fewer daily steps (R=-0.19, p=0.04), suggesting that depression may adversely affect important health behaviors. Increases in plasma BNP over 6 months were associated with worse outcomes. Changes in BDI-II score and plasma BNP over 6 months were positively correlated (R=0.25, p=0.004). This study underscores the importance of elevated depression symptoms and their association with an increased likelihood of adverse clinical outcomes in patients with HFrEF. Health behaviors may play a greater role than direct biobehavioral pathways in the adverse effects of depression on the HF disease trajectory and resultant clinical outcomes.